Enanta Pharmaceuticals (NASDAQ:ENTA) Getting Favorable Press Coverage, Report Shows
Media coverage about Enanta Pharmaceuticals (NASDAQ:ENTA) has been trending positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Enanta Pharma (ENTA) Sees Receiving $40M Milestone Following FDA Approval of AbbVie’s MAVYRET (streetinsider.com)
- Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks (finance.yahoo.com)
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significantly Higher Trading Volume (highlightpress.com)
- Featured Company News – EC Grants AbbVie’s MAVIRET Marketing Authorization for Treatment of Chronic Hepatitis C (finance.yahoo.com)
- Enanta (ENTA) Announce EC Grants AbbVie (ABBV) MAA for MAVIRet for Treatment of Chronic Hepatitis C in All Major Genotypes (streetinsider.com)
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded down 2.24% during midday trading on Thursday, reaching $38.82. 223,260 shares of the company’s stock traded hands. The stock’s market cap is $740.84 million. The stock has a 50 day moving average of $36.29 and a 200-day moving average of $32.18. Enanta Pharmaceuticals has a 52-week low of $21.00 and a 52-week high of $39.69.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.10. The firm had revenue of $9 million for the quarter, compared to the consensus estimate of $9.19 million. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The company’s revenue for the quarter was down 30.8% on a year-over-year basis. During the same period last year, the business posted ($0.09) EPS.
A number of equities analysts have recently commented on ENTA shares. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research report on Tuesday, July 11th. Finally, BidaskClub lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $30.75.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.